المساهمون: Lawrence Baruch, Staff Physician

المصدر: Comparative Efficacy of a Vytorin 10/80 Tablet Split Into 4 (Estimated Dose Ezetimibe 2.5 + Simvastatin 20) Versus Simvastatin 20 Milligrams on LDL Cholesterol

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00762164Test

المصدر: A Randomized, Double-Blind, Active-Controlled Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk and Not Adequately Controlled With Atorvastatin: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin Versus Doubling the Baseline Dose of Atorvastatin

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00782184Test

المؤلفون: Merck Sharp & Dohme LLC

المساهمون: Michael Miller, Dr.

المصدر: The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00819403Test

المساهمون: Andrei C. Sposito

المصدر: Additive Effect of Ezetimibe Upon Simvastatin Treatment on Systemic Inflammatory Activity and Endothelial Function During Myocardial Infarction

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00905905Test

المصدر: Post - Marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00909389Test

المساهمون: Kyung Mook Choi

المصدر: Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00926055Test

المؤلفون: Merck Sharp & Dohme LLC

المساهمون: Chu-Huang Chen, Principal Investigator

المصدر: Avogaro P, Cazzolato G, Btolo-Bon G. Some questns concerng a small, more electronegate LDL cculatg human plasma. Atheroscleros. 1991 Nov;91(1-2):163-71. do 10.1016/0021-9150(91)90198-c.
Ballantyne CM, HourJ, Notarbartolo A, MelanL, Lka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, VeltrEP; Ezete Study Group. Effect of ezete coadmtered wh atorvastat 628 patnts wh prary hypercholesterolem: a prospecte, randomed, double-bld trl. Cculatn. 2003 May 20;107(19):2409-15. do 10.1161/01.C.0000068312.21969.C8. Epub 2003 Apr 28.
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Hes G, Sharrett AR. Loprote-assocted phospholase A2, hh-sensy C-reacte prote, and rk for cent coronary heart dease mdle-aged men and women the Atheroscleros Rk Communs (AR) study. Cculatn. 2004 Feb 24;109(7):837-42. do 10.1161/01.C.0000116763.91992.F1. Epub 2004 Feb 2.
Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of trlycere-rh loprote remnant metabolm vceral obesy. Cl Chem. 2002 Feb;48(2):278-83.
Chen CH, Jng T, Yang JH, Jng W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, Mctyre TM, Henry PD, Yang CY. Low-densy loprote hypercholesterolem human plasma duces vascular endothell cell apoptos by hg froblast growth factor 2 transcrtn. Cculatn. 2003 Apr 29;107(16):2102-8. do 10.1161/01.C.0000065220.70220.F7. Epub 2003 Apr 14.
Chen CH, Pace PW, Karakoc ND, Lu J, Chen HH, Henry PD, Pownall HJ Foreyt JP, Ballantyne CM, Yang CY. Effecte reductn of novel atherogen LDL subfractn by atorvastat patnts wh hypercholesterem. J AM Coll Cardl. 2004:43(suppl A):486A (Abstract)
Chappey B, Myara Beno MO, Mazre C, Mazre JC, MoattN. Characterts of ten charge-dferg subfractns olated from human nate low-densy loprotes (LDL). No evence of peroxate modatns. Bch Bphys Acta. 1995 Dec 7;1259(3):261-70. do 10.1016/0005-2760(95)00172-7.
De Castellarnau C, Sanchez-Quesada JL, Benez S, Rosa R, Caveda L, Va L, Ordonez-Llanos J. Electronegate LDL from normolem subjects duces -8 and monocyte chemotact prote secretn by human endothell cells. Arterscler Thromb Vasc Bl. 2000 Oct;20(10):2281-7. do 10.1161/01.atv.20.10.2281.
Demuth K, Myara Chappey B, Ved B, Pech-Amsellem MA, Haberland ME, MoattN. A cytotox electronegate LDL subfractn present human plasma. Arterscler Thromb Vasc Bl. 1996 Jun;16(6):773-83. do 10.1161/01.atv.16.6.773.
Kleman Y, Krul ES, Burnes M, Aronson W, Pfleger B, Schonfeld G. Lolys of LDL wh phospholase A2 alters the expressn of selected apoB-100 epopes and the teractn of LDL wh cells. J L Res. 1988 Jun;29(6):729-43.
La Belle M, Blanche PJ, Krauss RM. Charge properts of low densy loprote subclasses. J L Res. 1997 Apr;38(4):690-700.
Lee SJ, Campos H, Moye LA, Sacks FM. LDL contag apoloprote C an dependent rk factor for coronary events dbet patnts. Arterscler Thromb Vasc Bl. 2003 May 1;23(5):853-8. do 10.1161/01.ATV.0000066131.01313.EB. Epub 2003 Mar 13.
Lby P. flammatn atheroscleros. Nature. 2002 Dec 19-26;420(6917):868-74. do 10.1038/nature01323.
Sanchez-Quesada JL, Benez S, Ordonez-Llanos J. Electronegate low-densy loprote. Curr Op Lol. 2004 Jun;15(3):329-35. do 10.1097/00041433-200406000-00014.
Sevann A, Btolo-Bon G, Cazzolato G, Hod H, Hwang J, ZamburlA, Maro M, UrsF. LDL- a l hydroperoxe-enrhed cculatg loprote. J L Res. 1997 Mar;38(3):419-28.
Steberg D. Lew A. Conner Memorl Lecture. Oxate modatn of LDL and atherogenes. Cculatn. 1997 Feb 18;95(4):1062-71. do 10.1161/01.c.95.4.1062. No abstract avaable.
Sons L, Tonkon M, Masana L, Maccubb D, Shah A, Lee M, Gumber B. Effects of ezete added to on-gog stat therapy on the l profe of hypercholesterolem patnts wh dbetes mellus or metabol syndrome. Curr Med Res Op. 2004 Sep;20(9):1437-45. do 10.1185/030079904x2321.
van Heek M, Aust TM, Farley C, Cook JA, Tetzloff GG, Dav HR. Ezete, a potent cholesterol absorptn hor, normales combed dyslem obese hypersulem hamsters. Dbetes. 2001 Jun;50(6):1330-5. do 10.2337/dbetes.50.6.1330.
Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smh CV. olatn, characteratn, and functnal assessment of oxately modd subfractns of cculatg low-densy loprotes. Arterscler Thromb Vasc Bl. 2003 Jun 1;23(6):1083-90. do 10.1161/01.ATV.0000071350.78872.C4. Epub 2003 Apr 10.
Yang CY, Chen HH, Huang MT, Raya JL, Yang JH, Chen CH, Gaubatz JW, Pownall HJ, Taylor AA, Ballantyne CM, Jennkens FA, Smh CV. Pro-apoptot low-densy loprote subfractns type dbetes. Atheroscleros. 2007 Aug;193(2):283-91. do 10.1016/j.atheroscleros.2006.08.059. Epub 2006 Oct 9.
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00988364Test

المؤلفون: Kaleida Health

المساهمون: Paresh Dandona, MD

المصدر: To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01420328Test

المساهمون: Dr. Lawrence Schachner, Chairman of department of Dermatology & Cutaneous Surgery

المصدر: AlA, Mart JM 4th. Ha growth patnts alopec areata total after treatment wh svastat and ezete. J Drugs Dermatol. 2010 Jan;9(1):62-4.
A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01520077Test

المصدر: A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01587235Test